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 Asthma is the most common chronic disease of child-hood, 1,2 and acute asthma is the most common 
pediatric emergency and reason for hospitalization. 
About 7% to 23% of patients with moderate or severe 
exacerbation are hospitalized. 3-5 Current guidelines 
recommend that patients with moderate or severe 
asthma exacerbation receive three doses of inhaled or 
nebulized  b -agonist in addition to ipratropium bromide 
every 15 to 20 min in the ﬁ rst hour. 6-9 Systemic corti-
costeroids given early following presentation to the 
ED decrease the rate of admission, especially in 
patients with more severe exacerbation. 10 
 Although several randomized controlled trials have 
shown clear efﬁ cacy of inhaled corticosteroids (ICSs) 
in the management of acute asthma as compared with 
placebo, 11,12 few studies have investigated the possi-
bility of an added beneﬁ cial effect of ICSs to systemic 
corticosteroids. 13-16 Surprisingly, however, these pilot 
studies demonstrated that high-dose nebulized budes-
onide can acutely improve peak ﬂ ow 15 and induce faster 
clinical improvement and hospital discharge. 14,17 Large, 
adequately powered studies, though, have not been per-
formed, and a Cochrane systematic review of ICS use 
for acute asthma suggested further study in this area. 11 
 Here, we hypothesized that adding high-dose budes-
onide (1,500  m g by nebulization) to the standard asthma 
treatment of children in the ED during the ﬁ rst hour 
would decrease their hospital admission rate. Finding 
 Background:  Inhaled corticosteroids, known to be effective as a maintenance medication in chronic 
asthma, have also been suggested as a therapy for acute asthma when given at high doses. 
 Methods:  A double-blind, randomized, placebo-controlled trial was conducted in children aged 
2 to 12 years with moderate or severe acute asthma, as determined based on a clinical score of 
5 to 15 points, where 15 is the most severe. We compared the addition of budesonide 1,500  m g 
vs placebo to standard acute asthma treatment, which included salbutamol, ipratropium bromide, 
and a single dose of prednisolone 2 mg/kg given at the beginning of therapy. The primary outcome 
was hospital admission rate within 4 h. 
 Results:  A total of 906 ED visits by children with moderate or severe acute asthma were evaluated. 
Seventy-ﬁ ve cases out of 458 (16.4%) in the budesonide group vs 82 of 448 (18.3%) in the placebo 
group were admitted (OR, 0.84; 95% CI, 0.58-1.23;  P  5 .38). However, among cases with high 
baseline clinical score (  13), signiﬁ cantly fewer children were admitted in the budesonide group 
(27 of 76 [35.5%]) than in the placebo group (39 of 73 [53.4%]; OR, 0.42; 95% CI, 0.19-0.94; 
 P  5 .03). 
 Conclusions:  The addition of budesonide nebulization did not decrease the admission rate of 
children with acute asthma overall. However, it may decrease the admission rate of children with 
severe acute asthma. 
 Trial registry:  ClinicalTrials.gov; No.: NCT01524198; URL: www.clinicaltrials.gov 
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 Abbreviations:  ICS  5 inhaled corticosteroid; LOS  5 length of stay 
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 Outcome Measures and Sample Size Determination 
 The primary outcome measure was admission rate evaluated 
at 4 h after administration of study-assigned treatment. Secondary 
outcomes were change in asthma score and total length of stay 
(LOS) in the ED. 
 Sample size was deemed sufﬁ cient to detect at least a 12% dif-
ferential between treatment groups in admission rate and a min-
imum of 90% statistical power with a two-sided 5% signiﬁ cance 
level. Additionally, sample size allowed for subgroup analysis using 
multiple comparisons criteria 19 to evaluate second-order interactions. 
The allocation of one-to-one treatment group was pursued using a 
permuted-block randomized scheme with variable block size. 
 Study Interventions 
 Eligible children were randomized within the pharmacy to 
receive three doses of budesonide solution (500  m g/dose) or pla-
cebo (normal saline). Patients also received  b -agonist (2.5 mg 
salbutamol if patient weight was  , 20 kg or 5 mg if   20 kg) and 
ipratropium 250  m g/dose. Budesonide or normal saline was deliv-
ered from the pharmacy in opaque syringes and were not distin-
guishable from each other. Respiratory therapists, who were not 
involved in patients’ recruitment or evaluation, mixed the deliv-
ered drug or placebo with salbutamol and ipratropium bromide. 
Normal saline was added to the treatment mixture to give a total 
volume of 3 mL/dose. They gave each patient one dose every 
20 min by jet nebulization over 1 h using an age-appropriate face 
mask. Patients also received prednisolone 2 mg/kg po with a max-
imum dose of 60 mg at the beginning of the study. All partici-
pating ED physicians underwent study protocol standardization 
and child-enrollment training. 
 Assessment of Children 
 All children were evaluated using the asthma scoring system 
( Table 1 ) at presentation (baseline) and at 1 h and 2 h from the 
start of medications. Patients who remained in the ED were also 
evaluated at 3 h and 4 h. A decision was made to admit or discharge 
patients at 2, 3, or 4 h. To be discharged, the child must have had 
no accessory muscle use, minimal or completely resolved wheezing, 
and oxygen saturation  . 92%. Children who were not ﬁ t for dis-
charge at 2-h or 3-h time points either had severe symptoms and 
signs and were admitted or had partially improved and so received 
additional salbutamol nebulizations according to their symptom 
severity or until they reached the 4-h time point. Discharged children 
were asked to continue prednisolone 2 mg/kg/d (maximum 60 mg) 
for 3 days in addition to  b -agonist as needed and their usual main-
tenance medications. At 72 h postdischarge, a follow-up phone 
call was conducted. 
 Statistical Analysis 
 Univariate testing using  x 2  or Fisher exact or Kruskal methods 
were adopted to compare groups in admission rate and ED LOS 
at 2, 3, or 4 h, whereas  t test and Wilcoxon methods were used to 
compare changes in asthma score. A multivariate statistical analysis 
plan allowed for the potential dependency in response due to 
reenrollments of a subset of children, using generalized linear 
mixed modeling techniques in SAS software, version 9.3 (SAS 
Institute Inc). 20 
 Results 
 Description of Study Cohort 
 A total of 723 children were enrolled in the 
study, of whom 139 were allowed to reenroll and be 
that the use of high-dose inhaled budesonide, indeed, 
reduces hospitalization could lead to an important new 
treatment modality for acute asthma. 
 Materials and Methods 
 Study Design and Participants 
 This was a double-blind, randomized, two-arm, parallel groups, 
placebo-controlled clinical trial to compare the efﬁ cacy of adding 
nebulized budesonide (1,500  m g) or placebo (normal saline) to 
the treatment of children with moderate or severe acute asthma. 
Enroll ment continued from November 2010 through March 2012. 
Children were eligible if they were aged 2 to 12 years, had physician-
diagnosed asthma or a previous episode of shortness of breath that 
responded to a  b 2 -agonist, and had presented to the ED with 
moderate or severe acute asthma exacerbation. Asthma severity 
was determined using a clinical scoring system adopted from 
Qureshi et al 18 ( Table 1 ). In this system, severe acute asthma was 
arbitrarily predeﬁ ned as a score   12 and moderate asthma as a 
score from 8 to 11. Children with either mild acute asthma or 
severe acute asthma in critical condition requiring nonstandard 
immediate intervention were excluded. In addition, children with 
heart disease, chronic lung disease other than asthma, or those who 
had received systemic steroids within the past 7 days were also 
excluded. Patients were allowed to enroll in the study more than 
once. This study was conducted in accordance with the amended 
Declaration of Helsinki. The institutional review board at King 
Fahad Medical City in Riyadh, Saudi Arabia, approved the proto-
col (approval No. 09-102), and written informed consent was 
obtained from all patients’ guardians. 
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448 in the placebo group). Study enrollment details 
are displayed in  Figure 1 .  At baseline, the overall 
mean   SD asthma score was 10.63   1.73, 30.9% 
rerandomized (105, twice; 26, three times; six, four 
times, and two, ﬁ ve times) to constitute 906 random-
ization assignments (458 in the budesonide group and 
 Table 1— Asthma Severity Score 18 
Variable 
Asthma Score
1 Point 2 Points 3 Points
Respiratory rate, breaths/min
Age, y
 2-3   34 35-39   40
 4-5   30 31-35   36
 6-12   26 27-30   31
  . 12   23 24-27   28
Oxygen saturation, %  . 95 on room air 90-95 on room air  , 90 on room air or supplemental oxygen
Auscultation Normal breathing or 
 end-expiratory wheezing
Expiratory wheezing Inspiratory and expiratory wheezing, 
 diminished breath sounds, or both
Retractions None or intercostal Intercostal and substernal Intercostal, substernal, and supraclavicular
Dyspnea Speaks in sentences or coos 
 and babbles
Speaks in partial sentences 
 or utters short cries
Speaks in single words or short phrases 
 or grunts
 Figure 1. Study enrollment chart. Seventy-six subjects were excluded because they declined to participate 
from the beginning of the study, and 110 declined after reading the consent form, which was fully explained.
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had severe exacerbation, the mean   SD age was 
5.52   2.76 years, 35% of patients were girls, and 90% 
had prior physician-diagnosed asthma. 
 Evaluation of Randomization Scheme and 
Interrater Reliability 
 Table 2 displays the groups’ baseline characteris-
tics. The table indicates lack of any signiﬁ cant dispar-
ities between both groups. There was no difference 
in the baseline asthma score as well. 
 Interrater reliability of scoring the severity of acute 
asthma was assessed using intraclass correlation. The 
ratings of three randomly selected physicians, out of 
15 participating physicians, were assessed and com-
pared on a pilot sample of 28 children with asthma who 
presented to the ED with acute asthma. The intraclass 
correlation coefﬁ cient was 0.85 (95% CI, 0.76-0.94). 
This indicated very good interrater reliability. 
 Evaluation of Treatment Effects 
 Hospital Admission:  In the overall study popula-
tion, 75 of 458 patients (16.4%) who received budes-
onide were admitted vs 82 of 448 patients (18.3%) 
who received placebo (OR, 0.84; 95% CI, 0.58-1.23; 
 P  5 .38). Subgroup analysis did not indicate any statis-
tical signiﬁ cance except for baseline severity with a score 
of   13 (severe group) vs  , 13 (moderate group). 
Among the severe group, 27 of 76 patients (35.5%) 
who received budesonide were admitted vs 39 of 
73 patients (53.4%) who received placebo (OR, 0.42; 
95% CI, 0.19-0.94;  P  5 .03). This implied a 58% reduc-
tion in the risk of admission in the budesonide group 
vs placebo group. Conversely, this also entailed a 
2.4-fold increase in the likelihood of admission in the 
placebo group vs the budesonide group. Only 16.3% of 
patients who were randomized more than once had 
severe acute asthma. Their distribution was not dif-
ferent bet ween the two study arms. 
 Asthma Score Change:  There was a sustained drop 
in the asthma score during patients’ stay in the ED in 
both groups, where maximum drop occurred during 
the ﬁ rst 2 h. Overall, the mean drop in asthma score 
from baseline to disposition was not signiﬁ cantly dif-
ferent between the budesonide group and the placebo 
group, with mean difference of  2 0.19 in favor of the 
budesonide group (95% CI,  2 0.42 to 0.04;  P  5 .11). 
However, for the severe asthma group, this drop was 
signiﬁ cantly lower in the patients treated with budes-
onide vs those given placebo at disposition, with a mean 
difference of  2 0.73 (95% CI,  2 1.33 to  2 0.13;  P  5 .02) 
( Fig 2A ). In addition, the overall difference in the drop 
of asthma score between the two groups at 2, 3, or 
4 h was not signiﬁ cant ( Fig 2B ). However, in patients 
with severe asthma, a steadily increasing difference in 
the drop of asthma score between the two study groups 
was noted starting from the second hour until the 
fourth hour, when it reached  2 0.87 in favor of the 
budesonide group (95% CI,  2 1.69 to  2 0.06;  P  5 .04) 
( Fig 2C ). 
 Table 2— Comparison of Baseline Demographics and Clinical Characteristics of Budesonide vs Placebo Groups 
Baseline Characteristics
Budesonide (458)
No. (%)
Placebo (448)
No. (%)  P Value
Age, y
 2-6 305 (66.59) 310 (69.20) .40
 7-12 153 (33.41) 138 (30.80) …
Female sex 156 (34.06) 161 (35.94) .55
Family history of asthma
 Parental (mother, father, or both) 208 (45.41) 199 (44.42) .76
 Siblings (one or more) 328 (71.62) 301 (67.15) .15
Smokers at home 83 (18.12) 86 (19.20) .68
Trigger, upper respiratory infection 385 (84.06) 394 (87.95) .09
Children with past medical history of:
 Admission to ward or PICU (lifetime) 196 (42.79) 208 (46.43) .45
 ED visits (in last year) 243 (53.06) 219 (48.88) …
 None 19 (4.15) 21 (4.69) …
 b 2 -Agonist inhalations (or equivalent nebulizers) during 
 the 6 h prior to presentation, No.
   5 32 (6.99) 22 (4.91) .34
 3-4 98 (21.40) 87 (19.42) …
 1-2 161 (35.15) 155 (34.60) …
 None 167 (36.46) 184 (41.07) …
Inhaled corticosteroid prophylaxis 120 (26.20) 117 (26.12) .98
Montelukast prophylaxis 31 (6.77) 33 (7.37) .73
PICU  5 pediatric ICU.
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and 2.64   0.79 h for the placebo group. None of 
these periods was signiﬁ cantly different between the 
two groups. 
 Adverse Effects:  The most frequently reported 
adverse effects were ﬁ ne tremors (17 cases) and pal-
pitations (11 cases). None of the reported adverse 
effects was serious, and none was signiﬁ cantly different 
between the two groups. 
 Postdischarge Follow-up:  Among 744 discharged 
cases, we were able to reach 641 cases (86.2%) by 
telephone 72 h postdischarge. In 606 cases (94.5%), 
improvement was reported, while 35 cases (5.5%) 
needed an unscheduled visit to a health-care facility. 
Among those, eight patients were admitted to the 
hospital (three in the budesonide group and ﬁ ve in the 
placebo group) and 27 were treated in the ED, then 
discharged (16 in the budesonide group and 11 in 
the placebo group). There was no statistically signiﬁ -
cant difference between the two groups in their out-
come at 72 h postdischarge. 
 Discussion 
 To our knowledge, the largest trial among the very 
limited number of randomized and blinded studies 
that have previously examined the addition of ICSs to 
systemic steroids in the treatment of acute asthma in 
the ED was by Upham et al. 16 They studied 180 chil-
dren with moderate to severe acute asthma and gave 
budesonide 2 mg in two divided doses. Using the same 
asthma score that we used, they found no difference 
in the admission rate, asthma score, and ED LOS 
between the two study arms, which is consistent with 
our ﬁ ndings in the overall study population. How-
ever, when we examined patients with severe acute 
asthma (score   13), we found a signiﬁ cantly lower 
admission rate and more drop in the asthma score in 
the budesonide group. In more practical terms, up to 
seven patients would need to be treated with budes-
onide to save one admission as compared with placebo. 
This would highly be cost effective, since 1-day admi s-
sion of a patient with severe acute asthma in our insti-
tution costs around $500 per night, while three doses 
of budesonide (500  m g/dose) costs about $7. This 
observation needs further study. The advantage of ICS 
in patients with severe acute asthma, as compared 
with moderate acute asthma, has been suggested in 
previous studies. 21-23 Additionally, giving ICS to patients 
with acute asthma carries an educational message 
about continuing ICS during these episodes. The 
adverse effects reported in our study are likely to be 
due to the  b -agonist. 11 
 A signiﬁ cant beneﬁ cial effect of high-dose ICS in 
this setting is counterintuitive, since potent systemic 
 ED Length of Stay:  The mean   SD LOS in the 
ED was 2.79   0.85 h for the budesonide group 
and 2.76   0.84 h for the placebo group. For patients 
with severe asthma, the mean   SD ED LOS was 
3.36   0.76 h for the budesonide group and 3.38   0.79 h 
for the placebo group; for patients with moderate 
asthma, it was 2.67   0.76 h for the budesonide group 
  
 Figure 2. A, Mean   95% CI drop in asthma score from baseline 
in budesonide vs placebo groups at disposition time in all patients 
and by baseline asthma severity status. * P  5 .02 for patients with 
severe acute asthma. B, Mean   95% CI drop in asthma score 
from baseline in budesonide vs placebo groups (taking all patients 
together) at the end of each hour time point of ED length of stay. 
C, Mean    95% CI drop in asthma score from baseline in budes-
onide vs placebo subgroups at the end of each hour time point of 
ED length of stay according to baseline asthma severity. * P  5 .04 
for patients with severe acute asthma at 4-h time point. 
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corticosteroids were used in all patients. 24 However, 
ICSs were shown to act earlier than systemic corti-
costeroids. For example, a signiﬁ cant decrement in 
sputum eosinophils was reported in patients with 
asthma after 2 h of the administration of inhaled ﬂ uti-
casone as compared with oral prednisone. 25 Moreover, 
a reduction in airway responsiveness to adenosine 
5 9 -monophosphate was demonstrated within 2 h after 
a single inhalation of ﬂ uticasone. 26 Such effects were 
presumed to be due to the topical nongenomic vaso-
constrictor action of ICS. 27,28 Based on the clinical 
efﬁ cacy and pharmacokinetics of ICS, it would be 
reasonable to speculate that using an equivalent dose of 
a different ICS administered by pressurized metered-
dose inhaler would have a similar effect. 29-31 
 In another interesting observation, we noticed that 
the relationship between the rate of admission and 
the patients’ scores was not linear. In other words, if 
we consider the asthma severity score range from 8 to 
15, we ﬁ nd that, on average, a one-point drop in the 
score decreases the likelihood of admission by 2.6-fold; 
looking only at scores   13, however, a one-point drop 
will decrease likelihood of admission by 4.1-fold. This 
has to be kept in mind when interpreting changes in 
the asthma score. 
 There are several limitations to our study. Our posi-
tive results relative to children with severe acute 
asthma need to be interpreted with caution because 
they were based on subgroup analysis, even though 
common confounders were taken into account when 
performing statistical analysis. Also, the deﬁ nition of 
severe acute asthma was a score of   12 according 
to the original score design, but our signiﬁ cant results 
were only demonstrated in patients with a score   13. 
The point of distinction between severe and mod-
erate exacerbation in the asthma score is arbitrary, 
nevertheless. We realize, however, that this was not a 
predeﬁ ned point, giving another reason for cautious 
interpretation. Moreover, the reenrollment of some 
subjects that was undertaken to increase the number 
of cases within our study time limitation could have 
introduced selection bias. This issue was taken into 
consideration, however, during the statistical analysis 
by using the generalized linear mixed modeling tech-
nique, and the randomization balance was maintained. 
In addition, we attempted to measure the peak expi-
ratory ﬂ ow rate in children  . 7 years old, but, unfor-
tunately, only very few reliably performed the test. 
This was not so sur prising, 32 especially because most 
of the patients were not pretrained to do it. Another 
limiting factor is that this is a single-center study, 
which may limit the generalizability of results. 
 In conclusion, our study did not show beneﬁ cial 
effect of the use of high-dose ICSs as add-on therapy 
to the current regimen in the treatment of mod-
erate to severe acute asthma in the ﬁ rst hour in the 
ED, but suggests a possible beneﬁ t in severe acute 
asthma. 
 Acknowledgments 
 Author contributions : Dr Alangari had full access to all of the 
data in the study and takes responsibility for the integrity of the 
data and the accuracy of the data analysis. 
 Dr Alangari: contributed to conception and design of the study; 
interpretation of data; and writing, review, and approval of the 
latest version of the manuscript and served as principal author. 
 Dr Malhis: contributed to study design and supervision, acquisi-
tion of data, and review and approval of the latest version of the 
manuscript. 
 Dr Mubasher: contributed to data analysis, writing the statistical 
section of the manuscript, and review and approval of the latest 
version of the manuscript. 
 Dr Al-Ghamedi: contributed to study design, drug dispensing, 
and review and approval of the latest version of the manuscript. 
 Dr Al-Tannir: contributed to study design, data management, and 
review and approval of the latest version of the manuscript. 
 Mr Riaz: contributed to data analysis and review and approval of 
the latest version of the manuscript. 
 Dr Umetsu: contributed to study design, manuscript preparation, 
and review and approval of the latest version of the manuscript. 
 Dr Al-Tamimi: contributed to study design, supervision of data 
collection, and review and approval of the latest version of the 
manuscript. 
 Financial/nonﬁ nancial disclosures : The authors have reported 
to  CHEST that no potential conﬂ icts of interest exist with any 
companies/organizations whose products or services may be dis-
cussed in this article. 
 Role of sponsors : The sponsor had no role in the design of the 
study, data collection, or data analysis . 
 References 
  1 .  Eder  W ,  Ege  MJ ,  von Mutius  E .  The asthma epidemic . 
N Engl J Med .  2006 ; 355 ( 21 ): 2226 - 2235 .  
  2 .  Subbarao  P ,  Mandhane  PJ ,  Sears  MR .  Asthma: epidemiology, 
etiology and risk factors .  CMAJ .  2009 ; 181 ( 9 ): E181 - E190 .  
  3 .  Rabe  KF ,  Vermeire  PA ,  Soriano  JB ,  Maier  WC .  Clinical man-
agement of asthma in 1999: the Asthma Insights and Reality 
in Europe (AIRE) study .  Eur Respir J .  2000 ; 16 ( 5 ): 802 - 807 .  
  4 .  Tsai  CL ,  Lee  WY ,  Hanania  NA ,  Camargo  CA  Jr .  Age-related 
differences in clinical outcomes for acute asthma in the United 
States, 2006-2008 .  J Allergy Clin Immunol .  2012 ; 129 ( 5 ):
 1252 - 1258 .  
  5 .  Pollack  CV  Jr ,  Pollack  ES ,  Baren  JM ,  et al ;  Multicenter 
Airway Research Collaboration Investigators .  A prospective 
multicenter study of patient factors associated with hospital 
admission from the emergency department among children 
with acute asthma .  Arch Pediatr Adolesc Med .  2002 ; 156 ( 9 ):
 934 - 940 .  
  6 . Global strategy for asthma management and prevention. 
Global Initiative for Asthma website.  http://www.ginasthma.org/
GINA-Report,-Global-Strategy-for-Asthma-Management-and-
Prevention . Updated December 2012. Accessed June 10, 2013. 
  7 . Expert panel report 3: guidelines for the diagnosis and man-
agement of asthma 2007. National Heart, Lung and Blood 
Institute website.  https://www.nhlbi.nih.gov/guidelines/asthma/
asthgdln.pdf . Accessed June 10, 2013. 
  8 .  Camargo  CA  Jr ,  Spooner  CH ,  Rowe  BH .  Continuous versus 
intermittent beta-agonists in the treatment of acute asthma . 
 Cochrane Database Syst Rev .  2003 ;( 4 ): CD001115 . 
  9 .  Rodrigo  GJ ,  Castro-Rodriguez  JA .  Anticholinergics in the 
treatment of children and adults with acute asthma: a sys-
tematic review with meta-analysis .  Thorax .  2005 ; 60 ( 9 ): 740 - 746 . 
778 Original Research
 21 .  Schuh  S ,  Dick  PT ,  Stephens  D ,  et al .  High-dose inhaled ﬂ uti-
casone does not replace oral prednisolone in children with mild 
to moderate acute asthma .  Pediatrics .  2006 ; 118 ( 2 ): 644 - 650 .  
  22 .  Schuh  S ,  Reisman  J ,  Alshehri  M ,  et al .  A comparison of inhaled 
ﬂ uticasone and oral prednisone for children with severe acute 
asthma .  N Engl J Med .  2000 ; 343 ( 10 ): 689 - 694 .  
 23 .  Rodrigo  GJ ,  Rodrigo  C .  Triple inhaled drug protocol for 
the treatment of acute severe asthma .  Chest .  2003 ; 123 ( 6 ): 
1908 - 1915 .  
 24 .  Manser  R ,  Reid  D ,  Abramson  M .  Corticosteroids for acute 
severe asthma in hospitalised patients .  Cochrane Database 
Syst Rev .  2001 ;( 1 ): CD001740 . 
  25 .  Belda  J ,  Margarit  G ,  Martínez  C ,  et al .  Anti-inﬂ ammatory effects 
of high-dose inhaled ﬂ uticasone versus oral prednisone in 
asthma exacerbations .  Eur Respir J .  2007 ; 30 ( 6 ): 1143 - 1149 .  
 26 .  Ketchell  RI ,  Jensen  MW ,  Lumley  P ,  Wright  AM ,  Allenby  MI , 
 O’Connor  BJ .  Rapid effect of inhaled ﬂ uticasone propionate 
on airway responsiveness to adenosine 5 9 -monophosphate in 
mild asthma .  J Allergy Clin Immunol .  2002 ; 110 ( 4 ): 603 - 606 .  
 27 .  Horvath  G ,  Wanner  A .  Inhaled corticosteroids: effects on the 
airway vasculature in bronchial asthma .  Eur Respir J .  2006 ;
 27 ( 1 ): 172 - 187 .  
 28 .  Alangari  AA .  Genomic and non-genomic actions of gluco-
corticoids in asthma .  Ann Thorac Med .  2010 ; 5 ( 3 ): 133 - 139 .  
 29 .  Bisgaard  H ,  Nikander  K ,  Munch  E .  Comparative study of 
budesonide as a nebulized suspension vs pressurized metered-
dose inhaler in adult asthmatics .  Respir Med .  1998 ; 92 ( 1 ): 44 - 49 .  
 30 .  Kelly  HW .  Establishing a therapeutic index for the inhaled 
corticosteroids: part I. Pharmacokinetic/pharmacodynamic 
comparison of the inhaled corticosteroids .  J Allergy Clin 
Immunol .  1998 ; 102 ( 4 pt 2 ): S36 - S51 .  
 31 .  Sims  MW .  Aerosol therapy for obstructive lung diseases: 
device selection and practice management issues .  Chest .  2011 ;
 140 ( 3 ): 781 - 788 .  
  32 .  Ducharme  FM ,  Davis  GM .  Measurement of respiratory resis-
tance in the emergency department: feasibility in young chil-
dren with acute asthma .  Chest .  1997 ; 111 ( 6 ): 1519 - 1525 .  
 10 .  Rowe  BH ,  Spooner  C ,  Ducharme  FM ,  Bretzlaff  JA ,  Bota 
 GW .  Early emergency department treatment of acute asthma 
with systemic corticosteroids .  Cochrane Database Syst Rev . 
 2001 ;( 1 ): CD002178 . 
 11 .  Edmonds  ML ,  Milan  SJ ,  Camargo  CA  Jr ,  Pollack  CV ,  Rowe 
 BH .  Early use of inhaled corticosteroids in the emergency 
department treatment of acute asthma .  Cochrane Database 
Syst Rev .  2012 ; 12 : CD002308 . 
 12 .  Rodrigo  GJ .  Rapid effects of inhaled corticosteroids in acute 
asthma: an evidence-based evaluation .  Chest .  2006 ; 130 ( 5 ):
 1301 - 1311 .  
 13 .  Guttman  A ,  Aﬁ lalo  M ,  Colacone  A ,  Kreisman  H ,  Dankoff  J ; 
 The Asthma ED Study Group .  The effects of combined intra-
venous and inhaled steroids (beclomethasone dipropionate) 
for the emergency treatment of acute asthma .  Acad Emerg 
Med .  1997 ; 4 ( 2 ): 100 - 106 .  
 14 .  Sung  L ,  Osmond  MH ,  Klassen  TP .  Randomized, controlled 
trial of inhaled budesonide as an adjunct to oral prednisone 
in acute asthma .  Acad Emerg Med .  1998 ; 5 ( 3 ): 209 - 213 .  
  15 .  Nuhoglu  Y ,  Atas  E ,  Nuhoglu  C ,  Iscan  M ,  Ozcay  S .  Acute effect 
of nebulized budesonide in asthmatic children .  J Investig 
Allergol Clin Immunol .  2005 ; 15 ( 3 ): 197 - 200 . 
 16 .  Upham  BD ,  Mollen  CJ ,  Scarfone  RJ ,  Seiden  J ,  Chew  A ,  Zorc 
 JJ .  Nebulized budesonide added to standard pediatric emer-
gency department treatment of acute asthma: a randomized, 
double-blind trial .  Acad Emerg Med .  2011 ; 18 ( 7 ): 665 - 673 .  
 17 .  Sano  F ,  Cortez  GK ,  Solé  D ,  Naspitz  CK .  Inhaled budesonide 
for the treatment of acute wheezing and dyspnea in children 
up to 24 months old receiving intravenous hydrocortisone . 
 J Allergy Clin Immunol .  2000 ; 105 ( 4 ): 699 - 703 .  
 18 .  Qureshi  F ,  Pestian  J ,  Davis  P ,  Zaritsky  A .  Effect of nebu-
lized ipratropium on the hospitalization rates of children with 
asthma .  N Engl J Med .  1998 ; 339 ( 15 ): 1030 - 1035 .  
 19 .  Hsu  JC .  Multiple Comparisons: Theory and Methods .  1st ed. 
 Boca Raton, FL :  Chapman & Hall/CRC ;  1996 . 
 20 .  Schall  R .  Estimation in generalized linear models with ran-
dom effects .  Biometrika .  1991 ; 78 ( 4 ): 719 - 727 .  
